Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

Newsfile January 16, 2024

AlloVir Investor Alert

Newsfile January 16, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

PR Newswire January 14, 2024

AlloVir Investor Alert

Newsfile January 14, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

Accesswire January 12, 2024

AlloVir Shareholder Action Reminder

Newsfile January 12, 2024

AlloVir Investor Alert

Newsfile January 10, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

Newsfile January 8, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

PR Newswire January 6, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of AlloVir, Inc. (ALVR)

Accesswire January 4, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AlloVir, Inc. - ALVR

Accesswire January 4, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of AlloVir, Inc. (ALVR)

Accesswire January 3, 2024

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

GlobeNewswire December 22, 2023

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire November 16, 2023

AlloVir Reports Third Quarter 2023 Financial Results

Business Wire November 2, 2023

AlloVir to Present at Upcoming Investor Conferences

Business Wire August 28, 2023

AlloVir Reports Second Quarter 2023 Financial Results

Business Wire August 3, 2023

AlloVir Announces Pricing of Public Offering of Common Stock

Business Wire June 21, 2023

AlloVir Announces Proposed Public Offering of Common Stock

Business Wire June 21, 2023

AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)

Business Wire June 5, 2023